



FULBRIGHT & JAWORSKI L.L.P.


A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

RECEIVED
JAN 09 2003
TECH CENTER 1600/2900

DAVID PARKER
PARTNER
DPARKER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3055
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

December 30, 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
<u>December 30, 2002</u> Date	 David L. Parker

Commissioner for Patents
Washington, D.C. 20231


Re: *SN 09/599,152 entitled "ETHYLENEDICYSTEINE (EC)-DRUG CONJUGATES, COMPOSITIONS AND METHODS FOR TISSUE SPECIFIC DISEASE IMAGING" by Yang et al.*
Our ref: UTXC:664/10020527 Client ref: MDA99-040

Commissioner:

Enclosed for filing in the above-referenced patent application are the following:

- (1) Response to Official Action Dated October 28, 2002; and
- (2) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

It is believed that no fee is due. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/UTSC:664.

Very truly yours,


David Parker
Reg. No. 32,165

DLP/lb
Enclosures

25191233.1



CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below.	
<u>December 30, 2002</u> Date	 David L. Parker

RECEIVED
JAN 09 2003
TECH CENTER 1600/2900

PATENT

P. TULLY
14/C
1-22-03
PRE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Yang, et al.

Serial No.: 09/599,152

Filed: June 21, 2000

For: ETHYLENEDICysteINE (EC)-DRUG
CONJUGATES, COMPOSITIONS AND
METHODS FOR TISSUE SPECIFIC
DISEASE IMAGING

Group Art Unit: 1619

Examiner: Jones, D.

Atty. Dkt. No.: UTXC:664

RESPONSE TO OFFICIAL ACTION DATED OCTOBER 28, 2002

Commissioner for Patents
Washington, D.C. 20231

Sir:

This paper is submitted in response to the Final Office Action dated October 28, 2002 for which the two-month date for response is December 28, 2002.

It is believed that no fees are due. However, should any fees be due, consider this paragraph such a request and authorization to withdraw the appropriate fee under 37 C.F.R. §§ 1.16 to 1.21 from Fulbright & Jaworski, L.L.P. Deposit Account No. 50-1212/UTXC:664.